Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab, Docetaxel, Cisplatin in Locally Advanced TET
NCT03858582Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Apr 2019
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in thymic epithelial tumor (TET) (3 arms), sponsored by Samsung Medical Center. Primary endpoint: Major Pathologic Response Rate at 36 months. Status: unknown.
02
Drugs
03
Conditions
thymic epithelial tumor (TET)
Beyond the preview
Go deeper on NCT03858582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03858582.